Neurophet

Neurophet EBITDA per Employee

The EBITDA per Employee of Neurophet (380550.KQ) as of Oct 15, 2026 is -122.59 M KRW. In the previous year, EBITDA per Employee was -89.68 M KRW — a change of 36.70% (lower).

EBITDA per Employee

-122.59 MKRW

YoY

36.70%

Last updated:

EBITDA per Employee of Neurophet is 2025 -122.59 M KRW. EBITDA per Employee of Neurophet was 2024 -89.68 M KRW. It decreases by 36.70% lower compared to the previous year.

The Neurophet EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2022
-69.74 M KRW
Jan 1, 2023
40.43 M KRW
Jan 1, 2024
-89.68 M KRW
Jan 1, 2025
-122.59 M KRW
The Neurophet EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-122.59 MKRW+36.70%
-89.68 MKRW-321.80%
40.43 MKRW-157.97%
-69.74 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurophet Stock analysis

What does Neurophet do? Neurophet Inc is a South Korean company operating in the Health Care sector, headquartered in Seoul. The company has 135 employees and is listed on the Korean stock exchange with the ticker 380550.KQ and ISIN KR7380550004. Neurophet Inc went public on July 25, 2025, marking its initial public offering. The company focuses on the research, development, and sales of brain imaging analysis software, including PET image quantitative analysis software called 'Neurophet SCALE PET' and neurodegenerative brain disease diagnosis support software named 'Neurophet AQUA'. Additionally, Neurophet Inc develops and sells therapeutic medical devices and provides medical artificial intelligence solutions. The company's website is https://www.neurophet.com/. Neurophet Inc operates within the Health Care Technology industry, specializing in software and AI-driven tools for medical imaging and diagnostics. The company's products are designed to support healthcare professionals in analyzing brain imaging data and diagnosing neurological conditions. As a technology-focused health care provider, Neurophet Inc aims to enhance diagnostic accuracy and efficiency through its software solutions. The company's operations are based in Seoul, South Korea, and it is engaged in both the development and commercialization of its medical technology products. Neurophet Inc's business model centers on creating innovative software tools that address specific challenges in neurology and brain imaging analysis. Neurophet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurophet stock

EBITDA per Employee of Neurophet is -122.59 M KRW in 2025.

EBITDA per Employee of Neurophet changed from -89.68 M KRW to -122.59 M KRW, representing a 36.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Neurophet since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Neurophet historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Neurophet

All Key Metrics — Neurophet